Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Juno Therapeutics, Inc. (JUNO)
|
Add to portfolio |
|
|
|
| Price: |
$86.96
| | Metrics |
| OS: |
116.1
|
M
| |
-39
|
% ROE
|
| Market cap: |
$10.1
|
B
| |
-62
|
% ROIC
|
|
Net cash:
|
$964
|
M
| |
$8.30
|
per share
|
|
EV:
|
$9.13
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($424)
|
M
| |
|
|
|
EBIT
|
($448)
|
M
| |
|
|
| EPS |
($4.15)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 111.9 | 79.4 | 18.2 | 0.0 |
| Revenue growth | 41.0% | 335.7% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 111.9 | 79.4 | 18.2 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | |
| Research and development | 451.5 | 264.3 | 205.2 | 204.5 |
| General and administrative | 108.1 | 70.7 | 57.2 | 28.2 |
| EBITA | -440.5 | -255.6 | -244.1 | -232.8 |
| EBITA margin | -393.7% | -322.1% | -1340.1% | |
| Amortization of intangibles | 7.3 | | | |
| EBIT | -447.8 | -255.6 | -244.1 | -232.8 |
| EBIT margin | -400.3% | -322.1% | -1340.1% | |
| Pre-tax income | -443.1 | -256.2 | -242.1 | -243.4 |
| Income taxes | -6.0 | -10.7 | -2.8 | 0.0 |
| Tax rate | 1.4% | 4.2% | 1.1% | 0.0% |
| Net income | -437.1 | -245.6 | -239.4 | -310.9 |
| Net margin | -390.7% | -309.5% | -1314.2% | |
| |
| Diluted EPS | ($4.10) | ($2.42) | ($2.72) | ($36.82) |
| Shares outstanding (diluted) | 106.7 | 101.5 | 88.1 | 8.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|